The accompanying article (Manzi, A., Salimath, P. V., Spiro, R. C., Keifer, P. A., and Freeze, H. H. (1995) J. Biol. Chem. 270, 9154-9163) reported the complete structure of a novel molecule made by human melanoma cells incubated with 1 mM 4-methylumbelliferyl-beta Xyl (Xyl beta MU). The product resembles a common pentasaccharide core region found in chondroitin/dermatan sulfate glycosaminoglycans, except that a terminal alpha-Gal-NAc residue is found in a location normally occupied by beta-GalNAc in these chains or alpha-GlcNAc in heparan sulfate chains. In this paper we show that several other human cancer cell lines and Chinese hamster ovary cells also make alpha-GalNAc-capped xylosides. The [6-3H]galactose-labeled Xyl beta MU product binds to immobilized alpha-GalNAc-specific lectin from Helix pomatia and the binding is competed by GalNAc, but not by Glc. Binding to the lectin is destroyed by digestion with alpha-N-acetylgalactosaminidase, but not beta-hexosaminidase. The nature of the aglycone influences the amount and relative proportion of this material made, with p-nitrophenyl-beta-xyloside being a better promoter of alpha-GalNAc-terminated product than Xyl beta MU. This novel oligosaccharide accounts for 45-65% of xyloside-based products made by both human melanoma and Chinese hamster ovary cells when they are incubated with 30 microM Xyl beta MU, but at 1 mM both the total amount and the proportion decreases to only 5-10%. In both cell lines this product is replaced by a corresponding amount of Sia alpha 2,3Gal beta 4Xyl beta MU. Preferential synthesis of the alpha-GalNAc-capped material at very low xyloside concentration argues that it is a normal biosynthetic product and not an experimental artifact. This pentasaccharide may be a previously unrecognized intermediate in glycosaminoglycan chain biosynthesis. Since this alpha-GalNAc residue occurs at a position that determines whether chondroitin or heparan chains are added to the acceptor, it may influence the timing, type, and extent of further chain elongation.
Manzi A, Salimath PV, Spiro RC, Keifer PA, Freeze HH
The Journal of biological chemistry •
beta-Xylosides compete with endogenous proteoglycan core proteins and act as alternate acceptors for synthesizing protein-free glycosaminoglycan chains. Their assembly on these alternate acceptors utilizes the same glycosyltransferases that make the protein-bound chains. Most studies using alternate acceptors focus on the production of sulfated glycosaminoglycan chains that are thought to be the major products. However, we previously showed that labeling melanoma cells with [6-3H]galactose in the presence of 4-methylumbelliferyl (MU) or p-nitrophenyl (pNP) beta-xylosides led to the synthesis of mostly di- to tetrasaccharide products including incomplete core structures. We have solved the structure of one of the previously unidentified products as, GalNAc alpha(1,4)GlcA beta(1,3)Gal beta(1,3)Gal beta(1,4)Xyl beta MU, based on compositional analysis by high performance liquid chromatography, fast atom bombardment, electrospray mass spectrometry, and one-dimensional and two-dimensional 1H NMR spectroscopy. The novel aspect of this molecule is the presence of a terminal alpha-Gal-NAc residue at a position that is normally occupied by beta-GalNAc in chondroitin/dermatan sulfate or by alpha-Glc-NAc in heparin or heparan sulfate chains. An alpha-GalNAc residue at this critical location may prevent further chain extension or influence the type of chain subsequently added to the common tetrasaccharide core.
Previous studies in many cell lines have shown that Brefeldin A (BFA) inhibits the forward movement of newly synthesized glycoconjugates by fusing the cis-, medial-, and trans-Golgi compartments with the rough endoplasmic reticulum. Studies on the oligosaccharide processing of individual glycoproteins have yielded confusing and incomplete results regarding the location of the block. Assuming that all glycoproteins with N-linked oligosaccharides follow the same endoplasmic reticulum to the Golgi pathway, a more complete picture on the location and nature of the block can be determined by analyzing N-linked oligosaccharides synthesized in the presence of BFA. In bovine pulmonary artery endothelial cells, BFA (0.1 microgram/ml) reversibly inhibits the secretion of greater than 95% of Tran35S and [3H]Man-labeled glycoproteins without affecting protein synthesis or N-linked glycosylation. In addition, BFA inhibits the synthesis and secretion of 35SO4-labeled oligosaccharides. Initial oligosaccharide trimming is uninhibited, but further processing is affected since the majority (65%) of the chains terminate only in beta-GlcNAc residues. Concomitantly, the proportion of [3H]Man-labeled N-linked anionic oligosaccharides is reduced from 60 to 20%, and the great majority of the charge is due to one sialic acid. The rate-limiting step for sialylation appears to be the branch selective addition of beta-Gal residues. The remaining charge is due to sulfate esters (0.6%) which normally account for greater than 10% of the anionic substituents. BFA also reduces the amount of phosphorylated chains by 80% and greatly diminishes further phosphodiester processing since the majority of these oligosaccharides (60%) contain a Man-6-PO4 residue in an acid-sensitive diester linkage. The addition of all polylactosamine chains, outer-branch fucose and terminal alpha-Gal residues are completely inhibited by BFA. Secretion, fucosylation, and sialylation are completely restored when BFA is removed, but the other modification steps are only partially restored. Our results indicate that addition of sulfate esters, terminal alpha-Gal residues, polylactosamine chains, outer-branch fucose residues, some initial phosphorylation, and most phosphodiester processing may occur beyond a compartment where some beta-Gal and sialic acid residues can be added. Essentially, all of the effects on oligosaccharide processing are partially or completely reversible.